» Articles » PMID: 32354115

Microbes and Cancer: Friends or Faux?

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2020 May 2
PMID 32354115
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer is one of the most aggressive and deadly diseases in the world, representing the second leading cause of death. It is a multifactorial disease, in which genetic alterations play a key role, but several environmental factors also contribute to its development and progression. Infections induced by certain viruses, bacteria, fungi and parasites constitute risk factors for cancer, being chronic infection associated to the development of certain types of cancer. On the other hand, susceptibility to infectious diseases is higher in cancer patients. The state of the host immune system plays a crucial role in the susceptibility to both infection and cancer. Importantly, immunosuppressive cancer treatments increase the risk of infection, by decreasing the host defenses. Furthermore, alterations in the host microbiota is also a key factor in the susceptibility to develop cancer. More recently, the identification of a tumor microbiota, in which bacteria establish a symbiotic relationship with cancer cells, opened a new area of research. There is evidence demonstrating that the interaction between bacteria and cancer cells can modulate the anticancer drug response and toxicity. The present review focuses on the interaction between microbes and cancer, specifically aiming to: (1) review the main infectious agents associated with development of cancer and the role of microbiota in cancer susceptibility; (2) highlight the higher vulnerability of cancer patients to acquire infectious diseases; (3) document the relationship between cancer cells and tissue microbiota; (4) describe the role of intratumoral bacteria in the response and toxicity to cancer therapy.

Citing Articles

Microbes, macrophages, and melanin: a unifying theory of disease as exemplified by cancer.

Berg S, Berg J Front Immunol. 2025; 15:1493978.

PMID: 39981299 PMC: 11840190. DOI: 10.3389/fimmu.2024.1493978.


Tumor microbiome: roles in tumor initiation, progression, and therapy.

Zhang S, Huang J, Jiang Z, Tong H, Ma X, Liu Y Mol Biomed. 2025; 6(1):9.

PMID: 39921821 PMC: 11807048. DOI: 10.1186/s43556-025-00248-9.


Dysbiosis and extraintestinal cancers.

He R, Qi P, Shu L, Ding Y, Zeng P, Wen G J Exp Clin Cancer Res. 2025; 44(1):44.

PMID: 39915884 PMC: 11804008. DOI: 10.1186/s13046-025-03313-x.


Intratumoral microbiota, fatty acid metabolism, and tumor microenvironment constitute an unresolved trinity in colon adenocarcinoma.

Liu G, Liu K, Ji L, Li Y Sci Rep. 2025; 15(1):2568.

PMID: 39833403 PMC: 11747563. DOI: 10.1038/s41598-025-87194-2.


The Role of Chronic Inflammation in Pediatric Cancer.

Mella C, Tsarouhas P, Brockwell M, Ball H Cancers (Basel). 2025; 17(1.

PMID: 39796780 PMC: 11719864. DOI: 10.3390/cancers17010154.


References
1.
Rollins K, Javanmard-Emamghissi H, Acheson A, Lobo D . The Role of Oral Antibiotic Preparation in Elective Colorectal Surgery: A Meta-analysis. Ann Surg. 2018; 270(1):43-58. PMC: 6570620. DOI: 10.1097/SLA.0000000000003145. View

2.
Anaissie E . Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis. 1992; 14 Suppl 1:S43-53. DOI: 10.1093/clinids/14.supplement_1.s43. View

3.
Kelly C, Lamont J . Clostridium difficile--more difficult than ever. N Engl J Med. 2008; 359(18):1932-40. DOI: 10.1056/NEJMra0707500. View

4.
Nakayama H, Kinouchi T, Kataoka K, Akimoto S, Matsuda Y, Ohnishi Y . Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics. 1997; 7(1):35-43. DOI: 10.1097/00008571-199702000-00005. View

5.
Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X . Prevention of Gastric Cancer: Eradication of Helicobacter Pylori and Beyond. Int J Mol Sci. 2017; 18(8). PMC: 5578089. DOI: 10.3390/ijms18081699. View